Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Do you know, that buy dildos is easy and safety?
Popular Articles

Topical Cream Studied As Way To Treat Skin Cancer Without The Knife
In a case study of a type of melanoma skin cancer typically found on chronically sun-exposed skin, Saint Louis University researchers found that imiquimod, a topical cream, produced good results for patients when used together with surgery to treat the cancer, potentially helping doctors cut less.
drugs without prescription
U.S. Moves Forward With Preparations For H1N1 Vaccination Campaign
The Obama administration on Thursday said a nationwide vaccination program could begin as early as mid-October to protect Americans from the H1N1 (swine flu) virus and pledged $350 million to help prepare communities across the country for this effort, the Washington Times reports (Ward, 7/9).
News of the day
North Carolina Residents Should Urge Lawmakers To Continue Funding HIV Program, Opinion Piece Says
The North Carolina legislature has proposed to eliminate the HIV Medicaid Case Management program, which "provides crucial support to people living with HIV, helping them access medical care, medications and the support services needed to live healthier lives," Jacquelyn Clymore of the Alliance of AIDS Services-Carolina and Beth Stringfield, member of the North Carolina AIDS Action Network, write in a Durham News opinion piece, adding, "We need to call legislators and let them know how important this program is to those living with HIV and ask them to return the program and its funding to the budget." They continue, "It is likely that additional budget cuts to HIV programs will be proposed, and we must speak out in support of state HIV prevention funding" (Clymore/Stringfield, Durham News, 6/13).
Oncology

ActoGeniX Obtains IND Approval

ActoGeniX, a development stage biopharmaceutical company, announced that the United States÷´ Food and Drug Administration (FDA) has approved the Company÷´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX÷´s portfolio. Oral mucositis is a painful inflammation of the oral mucosa affecting cancer patients and making daily activities such as eating, drinking and talking difficult or impossible. It is a severe and debilitating disease for which no effective cure is available today. AG013 is based on ActoGeniX÷´s proprietary TopAct™ platform and constitutes of an oral rinsing solution that delivers a potent healing factor to the damaged mucosa in the oral cavity. In preclinical pharmacology studies AG013 has already shown significant efficacy results suggesting that it holds great promise for the treatment of oral mucositis in cancer patients. ActoGeniX÷´s phase 1B clinical study will be conducted in six major oncology centers in the US, and will mainly evaluate safety and tolerability of the new product, but will also allow the collection of efficacy data. 21 Patients will be included in this placebo-controlled, single blinded, dose escalation study, which is expected to be completed during the first half of 2010. Dr. Mark Vaeck, CEO of ActoGeniX, commented: "We are extremely pleased with this approval by the FDA, which is a clear endorsement of the quality of our preclinical data package and development plan for AG013. Oral mucositis is a very significant and underserved opportunity in the cancer supportive care market, and a novel therapeutic product in this area has huge commercial potential." Dr. Bernard Coulie, Chief Medical Officer of ActoGeniX, added: "With the advancement into clinical development of AG013, our second lead product, ActoGeniX is well on its way to effectively build a significant clinical-stage product pipeline. Moreover AG013 could become the first approved therapy for oral mucositis in patients undergoing treatment of solid tumors or head/neck cancers." About Oral mucositis Oral mucositis is the (painful) inflammation, necrosis and ulceration of the oral mucosa, affecting nearly every patient that receives radiotherapy of the head/neck region or bone marrow transplant and a large proportion of solid tumor patients treated with chemotherapy or radiation therapy. Cardinal symptoms include ulcerations, debilitating pain and inability to eat and/or sustain anti-cancer therapy. Every year approximately 4 million new cases of cancer are diagnosed in the Western World, and almost 50% of those will develop oral mucositis. The economical costs due to oral mucositis are substantial, driven by the required additional medical care and extended hospital stay. ActoGeniX


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009